glp-1 substance use disorder GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and intake, though Medscape | Clinical evidence has

USA 101 , 1650116506 (2004)

More than 4 million items of tirzepatide and semaglutide were dispensed on the NHS in England in 2025/2026 1 , while around 2.5 million people each month accessed GLP-1s privately at the end of 2025, according to James Kingsland, chair of the Digital Clinical Excellence (DiCE) network of primary care digital health providers

Cell Investig

However, absorption often declines with age and can be impaired by digestive conditions (such as IBS, Crohns, or coeliac disease) and by certain medications (for example, long-term use of proton pump inhibitors)

If blood sugar management is part of the goal, clinicians may look at your day-to-day glucose patterns for early insight, while tracking longer-term markers like A1C changes and weight trends over time

If you want legitimate, clinician-led care, compare the top-rated online GLP-1 clinics for safe weight loss